New publication: Real-world study prospectively shows prognostic and predictive accuracy May 22, 2024 We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification an... Continue Reading
NICE in UK recommends EndoPredict® for tailored treatment of lymph node positive early breast cancer May 13, 2024 New guidance from the National Institute for Health and Care Excellence (NICE)1 The National Institute for Health and Care Excellence (NICE) in the UK has i... Continue Reading
Phase III validation of EndoPredict® confirms prognostic power May 6, 2024 Prognostic value of EndoPredict® test in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative primary breast cancer scre... Continue Reading
Updated ESMO Guidelines 2024 February 26, 2024 Level of Evidence (LoE) 1A for all gene expression assays in early ER+ HER2- breast cancer We are pleased to share the latest insights from the ESMO Clinica... Continue Reading
EndoPredict® at SABCS – Prospective long-term and real-world data December 16, 2022 Two prospective real-world studies presented at SABCS show EndoPredict® accurately guides decisions on chemotherapy in ER+, HER2- breast cancer 12th Decemb... Continue Reading
Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium September 19, 2022 Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Con... Continue Reading
EndoPredict informs treatment decisions for premenopausal breast cancer August 31, 2022 New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid ... Continue Reading
High adherence to EndoPredict test results in extended endocrine therapy decision making in early breast cancer June 9, 2022 Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making As a leader in genetic testing and ... Continue Reading
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer February 12, 2021 New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer Re... Continue Reading
German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at... Continue Reading